Lilly to Acquire Sigilon Therapeutics for Over $300M to Enhance its Cell Therapy Business for the Treatment of Type 1 Diabetes
Shots:
- As per the terms of the agreement, Lilly will launch a tender offer to purchase all outstanding shares of Sigilon for a price of $14.92 per share in cash, equal to $34.6M (payable at closing), plus a non-tradable CVR per share that entitles holders to receive up to $126.56 per share in cash, equal to $309.6M
- CVR holders would become entitled to receive (in cash) $4.06 per share upon first dosing of a specified product in the first human clinical trial, $26.39 per share for registration purposes & $81.19 per share upon receiving 1st regulatory approval
- Following the completion of the transaction (expected by Q3’23), Lilly will acquire any existing shares of Sigilon through a second-step merger at the same consideration as paid in the tender offer
Ref: PR Newswire | Image: Eli Lilly
Related News:- Eli Lilly to Acquire DICE Therapeutics for ~$2.4B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
